Eylea

[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?
[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?
Motley Fool
AbbVie
biosimilars
Humira
Clovis Oncology
Rubraca
Novartis
Regeneron
Eylea
Flag link:
Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron
Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron
Endpoints
Novartis
Eylea
Regeneron
RTH258
Flag link:
Regeneron posts mixed Q1 results, Eylea growth slows
Regeneron posts mixed Q1 results, Eylea growth slows
Drug Delivery Business News
Regeneron
earnings
Eylea
Flag link:
Clearside enrolls first patient in phase III trial of Zuprata combination therapy
Clearside enrolls first patient in phase III trial of Zuprata combination therapy
Drug Delivery Business News
Clearside Biomedical
Zuprata
Eylea
retinal vein occulsion
Flag link:
Regeneron revenue rises 11.7 pct on Eylea eye drug
Regeneron revenue rises 11.7 pct on Eylea eye drug
Yahoo/Reuters
Regeneron
earnings
Eylea
Flag link:
Biotechs line up to tap growing ophthalmics market
Biotechs line up to tap growing ophthalmics market
BioPharma Dive
Ophthalmic Drugs Market
Ocular Therapeutix
Eylea
Restasis
Lucentis
Regeneron
Roche
Allergan
Flag link:
Regeneron picks a new delivery tech in effort to upgrade flagship blockbuster Eylea
Regeneron picks a new delivery tech in effort to upgrade flagship blockbuster Eylea
Endpoints
Regeneron
Eylea
Ocular Therapeutix
drug delivery
Flag link:
Hard To See If Regeneron's Eylea Combo Study Failure Reads Through To Ophthotech's Fovista
Hard To See If Regeneron's Eylea Combo Study Failure Reads Through To Ophthotech's Fovista
Yahoo/Benzinga
Regeneron
Eylea
clinical trials
Ophthotech
Fovista
Flag link:
Regeneron's Eylea combination therapy fails mid-stage study
Regeneron's Eylea combination therapy fails mid-stage study
Yahoo/Reuters
Regeneron
Eylea
clinical trials
wet age-related macular degeneration
Flag link:
Bayer raises sales targets for top-selling drugs after Monsanto deal
Bayer raises sales targets for top-selling drugs after Monsanto deal
Yahoo/Reuters
Bayer
Monsanto
M&A
Xarelto
Eylea
Flag link:
Eylea sales lift Regeneron's profit past estimates
Eylea sales lift Regeneron's profit past estimates
Yahoo/Reuters
Regeneron
earnings
Eylea
Flag link:
Bayer hikes guidance as its pharma darlings Xarelto, Eylea power better-than-expected sales growth
Bayer hikes guidance as its pharma darlings Xarelto, Eylea power better-than-expected sales growth
Fierce Pharma
Bayer
earnings
Eylea
Xarelto
Flag link:
9 Drugs That Cost Medicare a Fortune
9 Drugs That Cost Medicare a Fortune
Motley Fool
Medicare
Lucentis
Eylea
Prolia
Treanda
Lexiscan
Yervoy
Privigen
Provenge
Soliris
Flag link:
Regeneron Eye Drug's Advantage Over Roche's Narrowed in Trial
Regeneron Eye Drug's Advantage Over Roche's Narrowed in Trial
Bloomberg
Regeneron
dry eye disease
Roche
Lucentis
Eylea
Flag link:
FDA sets LixiLan decision date for Sanofi-Novo diabetes showdown; Eylea could outshine Bayer's sales forecasts, analyst predicts
FDA sets LixiLan decision date for Sanofi-Novo diabetes showdown; Eylea could outshine Bayer's sales forecasts, analyst predicts
Fierce Pharma
FDA
LixiLan
Sanofi
Novo Nordisk
Bayer
Eylea
Flag link:
Regeneron: It’s the Eylea Outlook That Matters
Regeneron: It’s the Eylea Outlook That Matters
Barron's
Regeneron
Eylea
Flag link:
Will 2016 Be Regeneron Pharmaceuticals Inc.'s Best Year Yet?
Will 2016 Be Regeneron Pharmaceuticals Inc.'s Best Year Yet?
Motley Fool
Regeneron
Praluent
Eylea
Flag link:
Regeneron Tests Buy Point As New Drug Shows Promise
Regeneron Tests Buy Point As New Drug Shows Promise
Investors.com
Regeneron
Eylea
Sanofi
Flag link:
Regeneron Pharmaceuticals Inc (REGN) Stock Update: Praluent And Eylea Drive Future Growth
Regeneron Pharmaceuticals Inc (REGN) Stock Update: Praluent And Eylea Drive Future Growth
Bidness, ETC
Regeneron
Praluent
Eylea
Flag link:
The Next Blockbusters Could Be Balms For Aging Eyes
The Next Blockbusters Could Be Balms For Aging Eyes
Investors.com
age-related macular degeneration
Bayer
Regeneron
Ophthotech
Allergan
Novartis
Applied Genetic Technologies
Avalanche Biotechnologies
Roche
Lucentis
Eylea
Flag link: